European Society of Cardiology Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
Cypher DES: Johnson & Johnson/Cordis' Cypherdrug-eluting stent is significantly safer than bare-metal stents in complex cases where stents overlap, according to a meta-analysis of four Cypher trials presented by Martin Rothman, MD, London NHS Trust Hospital, at the European Society of Cardiology conference in Stockholm, Sept. 6. The analysis shows that overlapping Cypher stents are associated with a significantly lower rate of major adverse events than overlapping bare-metal stents - 7.4% versus 31.5% - and a lower rate of Q-wave myocardial infarction - 1.5% versus 4.6%. About 25% of all stent procedures require overlapping stents, according to Rothman. Studies included in the meta-analysis are SIRIUS, E-SIRIUS, DIRECT and SVELTE (1"The Gray Sheet" May 31, 2004, p. 13)...